MA35943B1 - Utilisation de (rs)-s-cyclopropyl-s-(4-{[4-{ [(1r, 2r)-2-hydroxy-1-méthylpropyl]oxy}-5-(trifluorméthyl) pyrimidin-2-yl]amino} - Google Patents
Utilisation de (rs)-s-cyclopropyl-s-(4-{[4-{ [(1r, 2r)-2-hydroxy-1-méthylpropyl]oxy}-5-(trifluorméthyl) pyrimidin-2-yl]amino}Info
- Publication number
- MA35943B1 MA35943B1 MA37365A MA37365A MA35943B1 MA 35943 B1 MA35943 B1 MA 35943B1 MA 37365 A MA37365 A MA 37365A MA 37365 A MA37365 A MA 37365A MA 35943 B1 MA35943 B1 MA 35943B1
- Authority
- MA
- Morocco
- Prior art keywords
- trifluormethyl
- methylpropyl
- cyclopropyl
- oxy
- hydroxy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne l'utilisation de (r)-s-cyclopropyl-s-(4-{[4-{[(1r, 2r)-2-hydroxy-1- méthylpropyl]oxy}-5-(trifluorméthyl)pyrimidin-2-yl]
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102012204506 | 2012-03-21 | ||
PCT/EP2013/055561 WO2013139734A1 (fr) | 2012-03-21 | 2013-03-18 | Utilisation de (rs)-s-cyclopropyl-s-(4-{[4-{[(1r, 2r)-2-hydroxy-1-méthylpropyl]oxy}-5-(trifluorméthyl)pyrimidin-2-yl]amino}phényl)sulfoximide pour traiter des tumeurs spécifiques |
Publications (1)
Publication Number | Publication Date |
---|---|
MA35943B1 true MA35943B1 (fr) | 2014-12-01 |
Family
ID=47891732
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA37365A MA35943B1 (fr) | 2012-03-21 | 2014-09-18 | Utilisation de (rs)-s-cyclopropyl-s-(4-{[4-{ [(1r, 2r)-2-hydroxy-1-méthylpropyl]oxy}-5-(trifluorméthyl) pyrimidin-2-yl]amino} |
Country Status (20)
Country | Link |
---|---|
US (1) | US20150051232A1 (fr) |
EP (1) | EP2827871A1 (fr) |
JP (1) | JP2015510910A (fr) |
KR (1) | KR20140135215A (fr) |
CN (1) | CN104220075A (fr) |
AP (1) | AP2014007915A0 (fr) |
AU (1) | AU2013234451A1 (fr) |
CA (1) | CA2867746A1 (fr) |
CL (1) | CL2014002472A1 (fr) |
EA (1) | EA201491732A1 (fr) |
HK (1) | HK1204294A1 (fr) |
MA (1) | MA35943B1 (fr) |
MX (1) | MX2014011240A (fr) |
PH (1) | PH12014502075A1 (fr) |
SA (1) | SA113340398B1 (fr) |
SG (1) | SG11201405386SA (fr) |
TN (1) | TN2014000391A1 (fr) |
TW (1) | TW201338779A (fr) |
WO (1) | WO2013139734A1 (fr) |
ZA (1) | ZA201406986B (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015071231A1 (fr) * | 2013-11-14 | 2015-05-21 | Bayer Pharma Aktiengesellschaft | Combinaisons de (rs)-s-cyclopropyl-s-(4-{[4-{[(1r,2r) -2-hydroxy-1-méthylpropyl]oxy}-5-(trifluorométhyl)pyrimidin-yl-2]amino}phenyl)sulfoximide pour le traitement de tumeurs |
SI3154594T1 (sl) | 2014-06-13 | 2023-10-30 | Bach Biosciences, Llc | FAP-aktivirana terapevtska sredstva in z njimi povezane uporabe |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1307271A (en) | 1970-06-25 | 1973-02-14 | Shell Int Research | Sulphoximine derivatives and their use in herbicidal compositions |
DE4029650A1 (de) | 1990-09-19 | 1992-03-26 | Hoechst Ag | 2-anilino-pyrimidine, verfahren zu ihrer herstellung, sie enthaltene mittel und ihre verwendung als fungizide |
CA2294244A1 (fr) | 1997-07-12 | 1999-01-21 | Cancer Research Campaign Technology Limited | Derives de purine inhibant la kinase dependant de la cycline |
US6440965B1 (en) | 1997-10-15 | 2002-08-27 | Krenitsky Pharmaceuticals, Inc. | Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system |
AU5438499A (en) | 1998-08-29 | 2000-03-21 | Astrazeneca Ab | Pyrimidine compounds |
GB9828511D0 (en) | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
JP4771576B2 (ja) * | 2000-06-12 | 2011-09-14 | 譲治 稲澤 | Gasc1遺伝子 |
GB0016877D0 (en) | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Chemical compounds |
RU2330024C2 (ru) | 2001-05-29 | 2008-07-27 | Шеринг Акциенгезельшафт | Ингибирующие cdk-киназы пиримидины, способ их получения и их применение в качестве лекарственных средств |
EP1483260A1 (fr) | 2002-03-11 | 2004-12-08 | Schering Aktiengesellschaft | 2-heteroaryle-pyrimidines inhibitrices de la kinase dependante des cyclines, leur production et leur utilisation comme medicaments |
AU2003276463A1 (en) * | 2002-11-06 | 2004-06-07 | Cyclacel Limited | Combination comprising a cdk inhibitor and cisplatin |
DE10349423A1 (de) | 2003-10-16 | 2005-06-16 | Schering Ag | Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
EP2179991A1 (fr) * | 2008-10-21 | 2010-04-28 | Bayer Schering Pharma Aktiengesellschaft | Dérivés d'anilino-pyrimidine substitués par sulfoximine en tant qu'inhibiteurs de CDK, leur fabrication et leur utilisation en tant que médicaments |
US8912194B2 (en) * | 2008-11-24 | 2014-12-16 | Nerviano Medical Sciences S.R.L. | CDK inhibitor for the treatment of mesothelioma |
ES2458872T3 (es) * | 2009-04-30 | 2014-05-07 | Novartis Ag | Derivados de imidazol y su uso como moduladores de quinasas dependientes de ciclina |
DE102010014426A1 (de) * | 2010-04-01 | 2011-10-06 | Bayer Schering Pharma Aktiengesellschaft | Verwendung neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren |
DE102010014427A1 (de) | 2010-04-01 | 2011-10-06 | Bayer Schering Pharma Aktiengesellschaft | Kombinationen neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren |
-
2013
- 2013-03-18 WO PCT/EP2013/055561 patent/WO2013139734A1/fr active Application Filing
- 2013-03-18 AU AU2013234451A patent/AU2013234451A1/en not_active Abandoned
- 2013-03-18 AP AP2014007915A patent/AP2014007915A0/xx unknown
- 2013-03-18 CN CN201380015167.9A patent/CN104220075A/zh active Pending
- 2013-03-18 JP JP2015500871A patent/JP2015510910A/ja active Pending
- 2013-03-18 EP EP13709923.0A patent/EP2827871A1/fr not_active Withdrawn
- 2013-03-18 SG SG11201405386SA patent/SG11201405386SA/en unknown
- 2013-03-18 US US14/387,075 patent/US20150051232A1/en not_active Abandoned
- 2013-03-18 EA EA201491732A patent/EA201491732A1/ru unknown
- 2013-03-18 CA CA2867746A patent/CA2867746A1/fr not_active Abandoned
- 2013-03-18 MX MX2014011240A patent/MX2014011240A/es unknown
- 2013-03-18 KR KR1020147026273A patent/KR20140135215A/ko not_active Application Discontinuation
- 2013-03-19 TW TW102109754A patent/TW201338779A/zh unknown
- 2013-03-20 SA SA113340398A patent/SA113340398B1/ar unknown
-
2014
- 2014-09-17 CL CL2014002472A patent/CL2014002472A1/es unknown
- 2014-09-18 TN TNP2014000391A patent/TN2014000391A1/fr unknown
- 2014-09-18 MA MA37365A patent/MA35943B1/fr unknown
- 2014-09-18 PH PH12014502075A patent/PH12014502075A1/en unknown
- 2014-09-25 ZA ZA2014/06986A patent/ZA201406986B/en unknown
-
2015
- 2015-05-26 HK HK15104968.3A patent/HK1204294A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
TW201338779A (zh) | 2013-10-01 |
ZA201406986B (en) | 2016-08-31 |
WO2013139734A1 (fr) | 2013-09-26 |
CN104220075A (zh) | 2014-12-17 |
HK1204294A1 (en) | 2015-11-13 |
EA201491732A1 (ru) | 2015-08-31 |
CA2867746A1 (fr) | 2013-09-26 |
KR20140135215A (ko) | 2014-11-25 |
US20150051232A1 (en) | 2015-02-19 |
JP2015510910A (ja) | 2015-04-13 |
EP2827871A1 (fr) | 2015-01-28 |
CL2014002472A1 (es) | 2014-12-12 |
MX2014011240A (es) | 2014-10-15 |
AU2013234451A1 (en) | 2014-09-25 |
PH12014502075A1 (en) | 2014-12-10 |
AP2014007915A0 (en) | 2014-09-30 |
SA113340398B1 (ar) | 2016-04-04 |
SG11201405386SA (en) | 2014-11-27 |
TN2014000391A1 (en) | 2015-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2016000327A (es) | (2r,5s,13ar)-7,9-dioxo-10-((2,4,6-trifluorobencil)carbamoil)-2,3,4,5,7,9,13,13a-octahidro-2,5-metanopirido[1,2:4,5]pirazino[2,1-b][1,3]oxazepin-8-olato de sodio | |
UY34824A (es) | Nucleósidos de espirooxetano de uracilo | |
UY34778A (es) | ?COMPUESTOS DE HEXAHIDROPIRANO[3,4-d][1,3]TIAZIN-2-AMINA HETEROCÍCLICOS SUSTITUÍDOS?. | |
UY34302A (es) | COMPUESTOS DE HEXAHIDROPIRANO[3,4-d][1,3]TIAZIN-2- AMINA | |
EA201491811A1 (ru) | АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ | |
PH12014502398A1 (en) | Pesticidal compositions and processes related thereto | |
UA110880C2 (uk) | Заміщені амідином бета-лактами, їх одержання та застосування як антибактеріальних засобів | |
EA201690461A1 (ru) | Полиморфные формы (s)-2-(1-(9h-пурин-6-иламино)пропил)-5-фтор-3-фенилхиназолин-4(3h)-она | |
UY34765A (es) | Compuestos novedosos. | |
UY34885A (es) | Proteínas de unión anti-mesotelina | |
UY34820A (es) | Compuestos tipo pirrolo-pirrolidinona | |
CR20150271A (es) | Peptidos como agonistas de oxitocina | |
MA37506A1 (fr) | Utilisations thérapeutiques de protéines de facteur de croissance des fibroblastes 21 | |
EA201592082A1 (ru) | 3,4-дигидроизохинолин-2(1h)-ильные соединения | |
MA35898B1 (fr) | Anticorps anti-lrp5 et leurs procédés d'utilisation | |
EA201590962A1 (ru) | Новые соединения | |
BR112015012907A2 (pt) | composição de cuidado pessoal | |
UY34629A (es) | Inhibidores de pirazolopirimidinilo de enzima activadora de ubicuitina | |
UY34329A (es) | Compuestos de triazolopiridina | |
CO6821958A2 (es) | Tetrahidroquinolinas condensadas con cicloalquilo como moduladores de receptores de crth2 | |
EA201590503A1 (ru) | Альфа-1-микроглобулин для применения в лечении заболеваний, связанных с митохондриями | |
UY34553A (es) | Procedimiento de preparación de la sal de l-arginina de perindoprilo | |
UY34191A (es) | ?N-(6-((2R,3S)-3,4-Dihidroxibutan-2-iloxi)-2-(4-fluorobenciltio)pirimidin-4-il)-3-metilazetidina-1-sulfonamida y sales farmacéuticamente aceptables de lamisma?. | |
NZ630549A (en) | N-ethyl-4-hydroxyl-1-methyl-5- (methyl(2,3,4,5,6-pentahydroxyhexyl) amino) -2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide | |
UY34677A (es) | Imidazopiridazinas sustituidas |